Please login to the form below

Not currently logged in
Email:
Password:

macular oedema

This page shows the latest macular oedema news and features for those working in and with pharma, biotech and healthcare.

Bicycle Therapeutics looks to raise $86m with IPO

Bicycle Therapeutics looks to raise $86m with IPO

The lead molecule of this partnership is THR-149, a novel plasma kallikrein inhibitor, for the treatment of diabetic macular oedema.

Latest news

  • After Lucentis setback, Novartis trumpets data on follow-up drug After Lucentis setback, Novartis trumpets data on follow-up drug

    The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD), ... In addition to nAMD, Novartis

  • Regeneron and Bayer drop AMD combination Regeneron and Bayer drop AMD combination

    Abandon plans after disappointing phase II trial results. Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival ... advance the duo into phase III in

  • Lucentis claims speedy FDA review for myopia complication Lucentis claims speedy FDA review for myopia complication

    in the EU myopic CNV market, adding to their rivalry in other indications such as wet age-related macular degeneration and diabetic macular oedema.

  • NICE backs Bayer’s Eylea as first-line BRVO treatment NICE backs Bayer’s Eylea as first-line BRVO treatment

    This treatment continues to achieve positive results in real-life clinical practice, similar to that demonstrated in clinical trials, and we hope that this will continue for patients with macular oedema ... its rivals in macular oedema Roche's Avastin

  • NICE gives Bayer's Elyea a provisional 'no' for first-line use NICE gives Bayer's Elyea a provisional 'no' for first-line use

    The provisional guidance in NICE's Appraisal Consultation Document only recommends Eylea in visual impairment in adults caused by macular oedema if laser photocoagulation has not been beneficial or is not ... NICE has previously recommended Eylea to

More from news
Approximately 8 fully matching, plus 36 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • RWE Blog 1: Real-world challenges and real-world data

    Greater improvement of key clinical outcomes  in patients with diabetic macular oedema from a real-world study of a fluocinolone intravitreal implant, compared with the results of the FAME (Fluocinolone Acetonide ... in Diabetic Macular Edema) RCTs.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Emotion-driven clinical trial marketing: A missed opportunity?
Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...

Infographics